Johnson & Johnson (NYSE:JNJ) Given New $250.00 Price Target at JPMorgan Chase & Co.

Johnson & Johnson (NYSE:JNJ) had its price target increased by JPMorgan Chase & Co. from $225.00 to $250.00 in a research report released on Thursday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research analysts have also issued reports on the stock. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a report on Friday, January 23rd. The Goldman Sachs Group reissued a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Citigroup lifted their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, HSBC upped their target price on Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $234.87.

Johnson & Johnson Stock Down 2.3%

Shares of NYSE:JNJ opened at $239.65 on Thursday. The firm has a market cap of $577.53 billion, a P/E ratio of 21.69, a P/E/G ratio of 2.42 and a beta of 0.34. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The business has a fifty day simple moving average of $227.70 and a 200 day simple moving average of $203.56. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s payout ratio is currently 47.06%.

Insider Buying and Selling

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last ninety days. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently added to or reduced their stakes in JNJ. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $25,000. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at $26,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the 4th quarter worth $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth $27,000. Finally, Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at about $28,000. Institutional investors own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval for TECVAYLI® (teclistamab) in combination with DARZALEX FASPRO® for relapsed/refractory multiple myeloma expands J&J’s label into earlier lines of therapy, with Phase 3 data showing significant progression‑free and overall survival benefits — a potential new standard of care and meaningful long‑term revenue upside for the oncology portfolio. PR Newswire: TECVAYLI + DARZALEX approval Reuters: FDA approves JNJ blood cancer drug
• Neutral Sentiment: JPMorgan raised its price target to $250 but kept a “neutral” rating — the higher target signals upside potential acknowledged by analysts, yet the maintained rating tempers immediate buy-side enthusiasm. Benzinga / TickerReport: JPMorgan price target
• Neutral Sentiment: J&J launched a direct‑to‑consumer website to sell certain drugs to uninsured or out‑of‑pocket U.S. patients — a strategic move to improve access and potentially capture incremental retail revenue, though initial impact on top line is uncertain. Reuters: direct-to-consumer site
• Neutral Sentiment: Pipeline progress: J&J is advancing nipocalimab (Fast Track for SLE) with Phase 3 underway — positive R&D momentum that supports future growth, offset by competing legal/claim disputes noted in coverage. Yahoo Finance: nipocalimab progress & legal challenge
• Negative Sentiment: Two J&J units agreed to pay $65 million to settle a Tracleer antitrust class action alleging overcharges — a direct legal expense and reminder of ongoing litigation risks, though the amount is modest versus J&J’s market cap. Reuters: $65M Tracleer settlement
• Negative Sentiment: Market reaction: coverage notes J&J shares declined more than the broader market during the session, reflecting that investors are weighing legal/settlement headlines and profit‑taking despite the positive FDA news. Zacks: JNJ declines more than market

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.